CHOLINERGIC FOUNDATIONS OF ALZHEIMERS-DISEASE THERAPY

Cholinesterase inhibitors (ChEI) represent the drug of choice for Alzh eimer's disease (AD) treatment. They produce significant improvement o n cognitive as well as non-cognitive function for a period up to 1 yea r during the first 3 years following clinical diagnosis. The magnitude of cognitive improvements is similar for different ChEI, however, dif ferences are seen with regard to incidence and severity of side effect s, optimal ChE inhibition, pharmacokinetic properties and mode of admi nistration. ((C)Elsevier, Paris).